Correlation of Wnt5a expression with histopathological grade/stage in urothelial carcinoma of the bladder
© Malgor et al.; licensee BioMed Central Ltd. 2013
Received: 26 April 2013
Accepted: 1 August 2013
Published: 15 August 2013
Bladder cancer, including urothelial carcinoma (UC), is the most common malignancy of the urinary tract and the fourth most frequent cancer overall in men. Wnt5a, a member of the Wnt family of proteins, has been shown to have contradictory roles in the pathogenesis of many cancers, acting either as tumor suppressor or tumor promoter. The objective of this study was to investigate the expression and role of Wnt5a in the pathogenesis of UC and suggest possible clinical applications for diagnosis, prognosis and treatment.
We characterized the expression of Wnt5a in 33 human UC samples using immunohistochemistry. The samples were obtained via transurethral resection, immediately fixed in formalin and then embedded in paraffin. The correlation between Wnt5a immunoreactivity, histological grade, and pathological stage of the tumor was analyzed. The expression of Wnt5a mRNA as well as the effect of Wnt5a on cell migration was also evaluated in two UC cell lines, T24 and J82, and a normal urothelial cell line.
Our immunohistochemical results revealed that Wnt5a staining intensity correlated positively with the histological grade and pathological stage of the UC. Wnt5a mRNA expression differed widely in the three urothelial cell lines, with high levels in one carcinoma cell line and low levels in the other cell line in comparison to the normal urothelial cell line. Migration increased in both UC cell lines in response to Wnt5a treatment.
Our results show that the Wnt5a pathway may play a role in the pathogenesis of UC and suggest that Wnt5a may serve as an additional, complementary diagnostic/prognostic marker for UC.
KeywordsBladder cancer Wnt5a Urothelial carcinoma Cell migration
Urinary bladder cancer is the fourth most frequent cancer overall in men in developed countries and the most common malignancy of the urinary tract[2, 3]. Worldwide, 297,338 new cases and 112,255 deaths due to bladder cancer in males were reported in 2008. In the United States, it is estimated that there will be 54,610 new cases of bladder cancer and 10,820 deaths in 2013. Approximately 95% of the tumors arising in the bladder originate in the urothelium, resulting in urothelial carcinoma (UC). Squamous cell carcinoma and adenocarcinoma are the other major forms of malignant tumors in the bladder.
Two important biological features of UC are its recurrence and its progression from superficial to invasive tumors. Approximately 50-65% of patients with noninvasive UC develop a recurrent tumor within 5 years after the first treatment. A majority of tumors at pTa stage are low grade and less than 5% of the tumors in this group will progress to a higher stage. In contrast, most of the tumors at pT1 pathological stage, which include tumors with invasion into the lamina propria, are high grade; 30-50% of the tumors in this group will progress to a higher stage[1, 2]. These features make UC challenging in clinical practice in relation to diagnosis, prognosis, treatment, or follow-up for each individual patient.
Wnt proteins are a group of secreted glycoproteins that play critical physiological roles during embryonic development, regulating cell proliferation, morphology, motility and fate. Aberrant Wnt signaling has been implicated in pathological conditions such as cancer and inflammatory diseases[6–10]. The canonical or β-catenin dependent signaling pathway is well recognized pathway in the Wnt family and is involved in normal cell growth and differentiation as well as in cancer. In the context of bladder cancers the hypermethylation of Wnt antagonist genes such as Wnt inhibitory factor 1 (WIF1), mutations in adenomatous polyposis coli (APC) and aberrant expression of β-catenin have been reported to be associated with increased aggressiveness and poor prognosis[11–15]. Recently, epigenetic deregulation of Wnt pathway inhibitors has been implicated in abnormal activation of the canonical Wnt signaling pathway in bladder tumors. All of these findings demonstrated the probable role of the canonical Wnt signaling pathway in the pathogenesis of UC of the bladder.
Wnt5a is a member of the Wnt family that belongs to a non- canonical/non- transforming signaling pathway. The non-canonical signaling involves numerous cellular pathways, all of them β-catenin-independent; however, based on the specific Wnt receptors present, Wnt5a can inhibit or promote β-catenin dependent signaling, which results in contradictory roles of Wnt5a in cancer. Wnt5a has been described as a tumor promoter and a tumor suppressor for different malignancies[6, 17]. It has been implicated in cancer progression as a potent enhancer of cell motility and invasiveness for malignant melanoma. Up-regulation of Wnt5a has been observed in lung, stomach, colon, breast, pancreas and prostate cancer as well[7, 19, 20]. The opposite function for Wnt5a, as a tumor suppressor, has been described in hematopoietic, brain, thyroid and colorectal cancers[21–23]. Specifically, Wnt5a has been shown to act as a tumor suppressor for colorectal carcinoma by antagonizing canonical Wnt/β-catenin signaling.
The role of Wnt5a in the pathogenesis/progression of UC has not been fully elucidated[14, 15]. Olson et al. reported the role of Wnt5a as a tumor suppressor gene in UC because ectopic expression of human Wnt5a in a UC cell line lacking the chromosomal region where Wnt5a resides abolished the cell’s tumorigenic capacity. Despite efforts to clarify the role of the non-canonical Wnt signaling pathway, and Wnt5a in particular, in the pathogenesis of UC, much is still unknown.
The aim of this study was to investigate the expression of Wnt5a protein in human UC. To accomplish this, we examined the expression of Wnt5a by immunohistochemistry (IHC) in 33 formalin-fixed, paraffin-embedded (FFPE) human UC samples. We found a significant positive correlation between Wnt5a expression and the histological grade and pathological stage of the tumor. Using in vitro methods, we also found that Wnt5a may be involved in the migration of malignant UC cells, which could have implications regarding the invasiveness of the tumor.
Materials and methods
Human urothelial carcinoma tissue specimens
Samples from 33 patients collected at the time of diagnostic/therapeutic transurethral resection and diagnosed as urothelial carcinoma of the bladder were included in this study. FFPE tissue blocks were archived at the University Medical Associates - Pathology Department (UMA-Pathology lab, Athens, OH). Ethical approval for the study was obtained from the Ohio University Institutional Review Board (IRB 07E112).
The diagnosis and classification of the 33 samples were performed according to the WHO/ISUP consensus classification system and the American College of Surgeon’s Cancer Program Standards. Hematoxylin and eosin (H&E) stains were used for diagnosis and staging of the tumors. Pathological stage was determined by the degree of invasion into the lamina propria. Histological grade was defined based on architecture, polarity, thickness, and cohesiveness, as well as cytologic features including pleomorphism, chromasia, presence of nucleoli, mitosis and umbrella cells.
FFPE tissue specimens were immunostained for Wnt5a using a Wnt5a polyclonal antibody. For each case, two consecutive 4 μm sections were mounted onto Superfrost glass slides. Sections were deparaffinized followed by antigen retrieval using 10 mM citrate buffer, pH 6.0, at 90°C for 30 minutes. Endogenous peroxidase activity was blocked with 3% H2O2 in phosphate buffered saline (PBS). Endogenous biotin and avidin were blocked using the Streptavidin/Biotin Blocking Kit (Vector Laboratories, Inc., Burlingame, CA). Rabbit polyclonal antibody against human Wnt5a (Santa Cruz Biotechnology, Santa Cruz, CA) was applied to one of the two sections at 4 μg/ml diluted in 1% bovine serum albumin (BSA), in PBS. As an isotype control, normal rabbit IgG (Invitrogen, Grand Island, NY) was applied to the other section at the same concentration. Slides were incubated overnight at 4°C in a humidified chamber. A peroxidase-based visualization kit, Universal LSAB™ + Kit/HRP, Rabbit/Mouse/Goat, was subsequently used according to the manufacturer’s protocol (Dako North America, Inc., Carpinteria, CA). Briefly, after three washes, the slides were incubated with the biotinylated secondary antibody for 20 minutes, washed three times, incubated with streptavidin-HRP for 20 minutes, developed with 3,3′-diaminobenzidine (DAB) chromogen (Sigma, St. Louis, MO) for 3 minutes, and counterstained with hematoxylin. Wnt5a staining was scored as the intensity of staining in tumor cells (ignoring staining in surrounding non-tumor tissue) on a scale of 0 (no staining) to 3 (high intensity) by two independent observers. Cases with discrepant scores were re-evaluated jointly until agreement was reached.
HTB-1™ (J82) and HTB-4™ (T24) urothelial carcinoma cell lines (ATCC, Manassas, VA) were cultured in Eagle’s Minimum Essential Medium and McCoy’s 5a Medium Modified, respectively, according to ATCC recommendations. The T24 cell line, characterized as non-tumorigenic, was derived from a poorly differentiated, high histological grade, recurrent tumor. The J82 cell line, with tumorigenic capacity, was derived from a poorly differentiated, high grade, invasive UC tumor. The normal urothelial cell (NUC) line (Lifeline Cell Technology, Walkersville, MD) was cultured in ProstaLife™ Prostate Epithelial Cell Culture Medium according to the manufacturer’s recommendations. Control conditioned medium (cCM) was prepared using L cells (CRL-2648™, ATCC) grown in ATCC-formulated Dulbecco’s Modified Eagle’s medium plus 10% fetal bovine serum. Wnt5a-conditioned medium (Wnt5aCM) was prepared using L Wnt-5A cells (CRL-2814™, ATCC) grown in Dulbecco’s Modified Eagle’s medium with 4 mM L-glutamine provided by ATCC and supplemented with 0.6 mg/ml G418 and 10% fetal bovine serum. For each conditioned medium, the cells were split 1:10 in culture medium (without G418) in 10 cm petri dishes and grown for 4 days. The medium was subsequently removed and sterilized by filtration (first batch of conditioned medium). Fresh culture medium (without G418) was added and cultured for 3 more days. The medium was removed again and sterilized as above (second batch of conditioned medium). The first and second batches were mixed 1:1 and kept frozen until needed.
Real time PCR
RNA was extracted from cells grown in 6-well plates using the RNeasy® Mini kit (Qiagen, Valencia, CA) following the manufacturer’s protocol. One microgram of RNA from each sample was reverse transcribed to cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). Real-time quantitative PCR was performed in duplicate for each sample using a gene-specific Taqman probe, Taqman™ Gene Expression Master Mix, and a StepOnePlus™ Real-Time PCR System according to the manufacturer’s protocol (Applied Biosystems, Foster City, CA). Wnt5a (Hs00180103_m1) and the following six potential housekeeping genes were assayed: HPRT (Hs99999909), GAPDH (Hs99999905), ACTB (Hs99999903), B2M (Hs99999907), UBC (Hs00824723), and SDHA (Hs00188166). The most stable housekeeping genes were selected for normalization purposes using the Normfinder algorithm as outlined by Andersen et al.. After normalization, data were presented as the fold change of Wnt5a RNA expression in each UC cell line relative to the level of expression observed in the NUC cells.
Migration of T24 and J82 cells was qualitatively examined by scratch assay and then quantified using the Oris™ Cell Migration Assay kit (Platypus Technologies, LLC, Madison, WI) according to the manufacturer’s protocol. For the scratch assay, T24 and J82 cells were grown to confluence. The monolayers were washed with PBS, a cross was scratched into the surface of each monolayer, and then the cells were incubated with either regular medium (RM) in which each cell line normally grew, or cCM or Wnt5aCM, prepared as described above. Cellular migration was observed and visually recorded at 24 h intervals.
For the Oris Cell Migration Assay, a 96-well plate was populated with silicone stoppers and cells were added to each well. When the cells were confluent, the stoppers were removed and the clear area defined as the area before migration. The cells were then incubated under four different conditions: RM, RM supplemented with recombinant Wnt5a (R&D Systems) at 100 ng/ml (rWnt5a), cCM or Wnt5aCM. The cells were allowed to grow for 24 hours and then migration was stopped by fixation with 10% formalin. Each well was digitally imaged and traced, with the migration area defined as the percentage of the previously clear area now occupied by cells after 24 hours of growth. The measurements were performed using Image-Pro® Plus (Media Cybernetics, Inc., Silver Spring, MD).
Logistic regression statistical analysis was performed to investigate the correlation between Wnt5a immunostaining and two variables, tumor histological grade and pathological stage. Cell migration was evaluated using t-tests to compare the effect of different treatments versus control. Statistical significance was tested at an alpha of 0.05. The software SPSS version 17 was used for data analysis (IBM SPSS, Armonk, NY).
Wnt5a immunostaining increases with increasing histological grade and pathological stage of the tumor
Histological grade and pathological stage were determined in all 33 samples of human UC included in the study. The samples were diagnosed as noninvasive papillary UC of low grade (12 samples), noninvasive papillary UC of high grade (8 samples) or invasive UC (13 samples, all high grade). For pathological stage of the disease, 20 of 33 cases were in pTa, 7 in pT1, 5 in pT2, and one could not be determined.
Correlation of Wnt5a staining intensity and histological grade of the tumors
Wnt5a staining intensity*
(n = 12)
(n = 21)
Correlation of Wnt5a staining intensity and pathological stage of the tumors
Wnt5a staining intensity*
(n = 20)
(n = 7)
(n = 5)
(n = 1)
Correlation of stage, grade and Wnt5a staining intensity
Number of cases
Staining intensity for low grade subset*
Staining intensity for high grade subset*
Wnt5a mRNA expression differs widely between urothelial cell lines
Exogenously applied Wnt5a results in different migration rates of UC cell lines
Urinary bladder cancer is the fourth most frequent cancer in men in the world today[1–3]. Due to its great plasticity and biological variability with respect to multifocality, recurrence, and invasion comportment, it is difficult to predict the behavior of an initially noninvasive UC[2, 3]. This feature makes the diagnosis of UC challenging, not only for its early detection, but also for accurate prediction of tumor recurrence and progression.
Multiple biomarkers used for other cancers have been described with potential diagnostic or prognostic value for UC as well, including p53, cytokeratin 20, E-cadherin, Ki67, CD44 and survivin[27, 28]. Currently a combination of these immunohistochemical biomarkers assayed within panel is the best way to characterize subtypes and predict the behavior/aggresiveness of UC. More recently, other promising biomarkers for UC have been reported. In a large retrospective exploratory study, expression of microRNA-100 was negatively associated with stage, recurrence, prognosis and death of patients with bladder cancer. In another large study, the cell surface zinc-dependent metalloprotease CD10 was strongly correlated with tumor grade and stage and possibly associated with tumor progression in bladder cancer pathogenesis. In contrast to initial studies correlating increased COX-2 expression and recurrence of urinary bladder cancer, a large study focused on non-muscle invasive bladder cancer found that lower levels of COX-2 and tumor-infiltrating lymphocytes were predictive of recurrence, suggesting the need of close follow-up and adjuvant therapy for these patients. In the current study Wnt5a protein expression by malignant cells was observed in all 33 samples included in the study; however, intensities, and hence protein levels, varied, correlating with both grade and stage and suggesting that Wnt5a may also serve as a biomarker of UC. To prove the predictive nature of Wnt5a as a diagnostic or prognostic biomarker of UC, further investigation into the relationship between Wnt5a expression by the tumor and clinical progression of the disease in a large number of patients, is required.
Expression of Wnt5a by UC tumor cells may also be a predictor of an aggressive subgroup of UC. We found that weak Wnt5a expression was predominantly seen in low grade UC samples and all were in a noninvasive (pTa) stage. This suggests that low Wnt5a expression may be indicative of non-aggressive tumors. In contrast, moderate to strong Wnt5a expression was seen in all three pathological stages, but was usually associated with high grade, high stage tumors. Thus, moderate to strong expression of Wnt5a is likely to indicate an aggressive tumor or transformation to an invasive phenotype. In support of this hypothesis previous studies have reported the role of Wnt5a as a pro-angiogenic gene[32, 33] and also the importance of the Wnt signaling pathway in epithelial-mesenchymal transition (EMT) of cancer. In addition, Huang CL et al. reported the association of Wnt5a with tumor proliferation in non-small-cell lung cancer (NSCLC); the authors concluded that overexpression of Wnt5a could increase aggressiveness in NSCLC.
The present study also assessed Wnt5a mRNA expression in two UC cell lines, both from high grade, poorly differentiated tumors. Interestingly, the expression differed significantly between them, with one of the cancer cell lines expressing much higher levels and the other expressing much lower levels of Wnt5a mRNA in comparison to the normal urothelial cell line. This result is similar to the result published many years ago by Bui et al. in which they described different Wnt5a mRNA expression levels for different UC cell lines. In that study the authors suggested that Wnt5a may modulate cell shape and cell migration.
In support of a role of Wnt5a in cell migration, Wnt5a has been associated with migration ability in melanoma. Our group previously reported constitutive Wnt5a expression in human pancreatic cancer and malignant melanoma cell lines and suggested the role of Wnt5a in growth and migration in both of these cancer cell lines. In this study we investigated migration response to exogenously applied Wnt5a in the two UC cell lines. We found that the T24 cell line, which has a low level of Wnt5a transcription, showed a significant increase in migration rate while J82, with high Wnt5a transcription, did not significantly respond to the application of Wnt5a. It is possible that J82, with high Wnt5a RNA, is already maximally saturated by Wnt5a and cannot respond further, while T24, with low Wnt5a RNA, is sub-maximally saturated and thus capable of responding to exogenous Wnt5a. Alternatively, it is possible that different cell lines have different responses to Wnt5a due to expression of different Wnt5a receptors. It is well known that the interaction between Wnt ligands and their receptors determine the signaling that will be activated, and multiple receptors may respond to Wnt5a signaling, each leading to activation of different downstream signaling pathways and effects[17, 37, 38]. Therefore, different responses might be associated with the presence of different receptors for Wnt5a ligand in each tumor cell line.
In conclusion, our results support previous work suggesting that the Wnt5a signaling pathway plays a pathological role in UC. The correlation of Wnt5a protein expression in UC tissue sections with histological grade and pathological stage of the tumor suggests its possible use as diagnostic/prognostic tool for UC. Further studies to investigate association between Wnt5a expression, tumor behavior and clinical outcome are necessary to fully validate the utility of Wnt5a for early diagnosis/prognosis of UC. Further studies are also needed to clarify the underlying mechanisms connecting Wnt5a and different tumor behavior. These investigations promise to deliver predictability for a relatively unpredictable cancer.
This study was supported in part by an Ohio University Heritage College of Osteopathic Medicine Research & Scholarly Affairs Committee (RSAC) Award.
- Foster CS, Ross JS: Pathology of the Urinary Bladder. 2004, Saunders: Philadelphia, PA, 183-190. 199–209; 247–267, 1Google Scholar
- Kausch I, Bohle A: Bladder cancer. II. Molecular aspects and diagnosis. Eur Urol. 2001, 39 (5): 498-506. 10.1159/000052495.View ArticlePubMedGoogle Scholar
- DeVita VT, Lawrence TS, Rosenberg SA: Cancer Principles & Practice of Oncology. 2011, 241-243. 1183–1189, 9Google Scholar
- American Cancer Society: Cancer Facts & Figures 2013. 2013, Atlanta: American Cancer Society Inc.Google Scholar
- Dale TC: Signal transduction by the Wnt family of ligands. Biochem J. 1998, 329 (Pt 2): 209-223.PubMed CentralView ArticlePubMedGoogle Scholar
- Nishita M, Enomoto M, Yamagata K, Minami Y: Cell/tissue-tropic functions of Wnt5a signaling in normal and cancer cells. Trends Cell Biol. 2010, 20 (6): 346-354. 10.1016/j.tcb.2010.03.001.View ArticlePubMedGoogle Scholar
- Dejmek J, Dejmek A, Safholm A, Sjolander A, Andersson T: Wnt-5a protein expression in primary dukes B colon cancers identifies a subgroup of patients with good prognosis. Cancer Res. 2005, 65 (20): 9142-9146. 10.1158/0008-5472.CAN-05-1710.View ArticlePubMedGoogle Scholar
- McCall KD, Harii N, Lewis CJ, Malgor R, Kim WB, Saji M, Kohn AD, Moon RT, Kohn LD: High basal levels of functional toll-like receptor 3 (TLR3) and noncanonical Wnt5a are expressed in papillary thyroid cancer and are coordinately decreased by phenylmethimazole together with cell proliferation and migration. Endocrinology. 2007, 148 (9): 4226-4237. 10.1210/en.2007-0459.View ArticlePubMedGoogle Scholar
- Blumenthal A, Ehlers S, Lauber J, Buer J, Lange C, Goldmann T, Heine H, Brandt E, Reiling N: The Wingless homolog WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation. Blood. 2006, 108 (3): 965-973. 10.1182/blood-2005-12-5046.View ArticlePubMedGoogle Scholar
- Christman MA, Goetz DJ, Dickerson E, McCall KD, Lewis CJ, Benencia F, Silver MJ, Kohn LD, Malgor R: Wnt5a is expressed in murine and human atherosclerotic lesions. Am J Physiol Heart Circ Physiol. 2008, 294 (6): H2864-H2870. 10.1152/ajpheart.00982.2007.View ArticlePubMedGoogle Scholar
- Shiina H, Igawa M, Shigeno K, Terashima M, Deguchi M, Yamanaka M, Ribeiro-Filho L, Kane CJ, Dahiya R: Beta-catenin mutations correlate with over expression of C-myc and cyclin D1 Genes in bladder cancer. J Urol. 2002, 168 (5): 2220-2226. 10.1016/S0022-5347(05)64359-5.View ArticlePubMedGoogle Scholar
- Kastritis E, Murray S, Kyriakou F, Horti M, Tamvakis N, Kavantzas N, Patsouris ES, Noni A, Legaki S, Dimopoulos MA, et al.: Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication. Int J Cancer. 2009, 124 (1): 103-108. 10.1002/ijc.23917.View ArticlePubMedGoogle Scholar
- Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoehr R, Woenckhaus M, Kristiansen G, Hsieh JC, Hofstaedter F, Hartmann A, et al.: WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol. 2003, 201 (2): 204-212. 10.1002/path.1449.View ArticlePubMedGoogle Scholar
- Urakami S, Shiina H, Enokida H, Hirata H, Kawamoto K, Kawakami T, Kikuno N, Tanaka Y, Majid S, Nakagawa M, et al.: Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res. 2006, 12 (23): 6989-6997. 10.1158/1078-0432.CCR-06-1194.View ArticlePubMedGoogle Scholar
- Urakami S, Shiina H, Enokida H, Kawakami T, Tokizane T, Ogishima T, Tanaka Y, Li LC, Ribeiro-Filho LA, Terashima M, et al.: Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. Clin Cancer Res. 2006, 12 (2): 383-391. 10.1158/1078-0432.CCR-05-1344.View ArticlePubMedGoogle Scholar
- Costa VL, Henrique R, Ribeiro FR, Carvalho JR, Oliveira J, Lobo F, Teixeira MR, Jeronimo C: Epigenetic regulation of Wnt signaling pathway in urological cancer. Epigenetics. 2010, 5 (4): 343-351. 10.4161/epi.5.4.11749.View ArticlePubMedGoogle Scholar
- McDonald SL, Silver A: The opposing roles of Wnt-5a in cancer. Br J Cancer. 2009, 101 (2): 209-214. 10.1038/sj.bjc.6605174.PubMed CentralView ArticlePubMedGoogle Scholar
- Weeraratna AT, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M, Trent JM: Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell. 2002, 1 (3): 279-288. 10.1016/S1535-6108(02)00045-4.View ArticlePubMedGoogle Scholar
- Schwartz AL, Malgor R, Dickerson E, Weeraratna AT, Slominski A, Wortsman J, Harii N, Kohn AD, Moon RT, Schwartz FL, et al.: Phenylmethimazole decreases Toll-like receptor 3 and noncanonical Wnt5a expression in pancreatic cancer and melanoma together with tumor cell growth and migration. Clin Cancer Res. 2009, 15 (12): 4114-4122. 10.1158/1078-0432.CCR-09-0005.PubMed CentralView ArticlePubMedGoogle Scholar
- Kurayoshi M, Oue N, Yamamoto H, Kishida M, Inoue A, Asahara T, Yasui W, Kikuchi A: Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res. 2006, 66 (21): 10439-10448. 10.1158/0008-5472.CAN-06-2359.View ArticlePubMedGoogle Scholar
- Blanc E, Goldschneider D, Douc-Rasy S, Benard J, Raguenez G: Wnt-5a gene expression in malignant human neuroblasts. Cancer Lett. 2005, 228 (1–2): 117-123.View ArticlePubMedGoogle Scholar
- Kremenevskaja N, von Wasielewski R, Rao AS, Schofl C, Andersson T, Brabant G: Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene. 2005, 24 (13): 2144-2154. 10.1038/sj.onc.1208370.View ArticlePubMedGoogle Scholar
- Ying J, Li H, Yu J, Ng KM, Poon FF, Wong SC, Chan AT, Sung JJ, Tao Q: WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer. Clin Cancer Res. 2008, 14 (1): 55-61. 10.1158/1078-0432.CCR-07-1644.View ArticlePubMedGoogle Scholar
- Olson DJ, Gibo DM, Saggers G, Debinski W, Kumar R: Reversion of uroepithelial cell tumorigenesis by the ectopic expression of human wnt-5a. Cell Growth Differ. 1997, 8 (4): 417-423.PubMedGoogle Scholar
- Masters JR, Hepburn PJ, Walker L, Highman WJ, Trejdosiewicz LK, Povey S, Parkar M, Hill BT, Riddle PR, Franks LM: Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines. Cancer Res. 1986, 46 (7): 3630-3636.PubMedGoogle Scholar
- Andersen CL, Jensen JL, Orntoft TF: Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004, 64 (15): 5245-5250. 10.1158/0008-5472.CAN-04-0496.View ArticlePubMedGoogle Scholar
- Chen YB, Tu JJ, Kao J, Zhou XK, Chen YT: Survivin as a useful adjunct marker for the grading of papillary urothelial carcinoma. Arch Pathol Lab Med. 2008, 132 (2): 224-231.PubMedGoogle Scholar
- Coleman JF, Hansel DE: Utility of diagnostic and prognostic markers in urothelial carcinoma of the bladder. Adv Anat Pathol. 2009, 16 (2): 67-78. 10.1097/PAP.0b013e318199f89e.View ArticlePubMedGoogle Scholar
- Wang S, Xue S, Dai Y, Yang J, Chen Z, Fang X, Zhou W, Wu W, Li Q: Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer. Diagn Pathol. 2012, 7: 159-10.1186/1746-1596-7-159.PubMed CentralView ArticlePubMedGoogle Scholar
- Bahadir B, Behzatoglu K, Bektas S, Bozkurt ER, Ozdamar SO: CD10 expression in urothelial carcinoma of the bladder. Diagn Pathol. 2009, 4: 38-10.1186/1746-1596-4-38.PubMed CentralView ArticlePubMedGoogle Scholar
- Tadin T, Krpina K, Stifter S, Babarovic E, Fuckar Z, Jonjic N: Lower cyclooxygenase-2 expression is associated with recurrence of solitary non-muscle invasive bladder carcinoma. Diagn Pathol. 2012, 7: 152-10.1186/1746-1596-7-152.PubMed CentralView ArticlePubMedGoogle Scholar
- Masckauchan TN, Agalliu D, Vorontchikhina M, Ahn A, Parmalee NL, Li CM, Khoo A, Tycko B, Brown AM, Kitajewski J: Wnt5a signaling induces proliferation and survival of endothelial cells in vitro and expression of MMP-1 and Tie-2. Mol Biol Cell. 2006, 17 (12): 5163-5172. 10.1091/mbc.E06-04-0320.PubMed CentralView ArticlePubMedGoogle Scholar
- Coffelt SB, Tal AO, Scholz A, De Palma M, Patel S, Urbich C, Biswas SK, Murdoch C, Plate KH, Reiss Y, et al.: Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res. 2010, 70 (13): 5270-5280. 10.1158/0008-5472.CAN-10-0012.View ArticlePubMedGoogle Scholar
- Voutsadakis IA: The ubiquitin-proteasome system and signal transduction pathways regulating Epithelial Mesenchymal transition of cancer. J Biomed Sci. 2012, 19: 67-10.1186/1423-0127-19-67.PubMed CentralView ArticlePubMedGoogle Scholar
- Huang CL, Liu D, Nakano J, Ishikawa S, Kontani K, Yokomise H, Ueno M: Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor–an expression in non-small-cell lung cancer. Journal of clinical oncology:. 2005, 23 (34): 8765-8773. 10.1200/JCO.2005.02.2871.View ArticleGoogle Scholar
- Bui TD, O’Brien T, Crew J, Cranston D, Harris AL: High expression of Wnt7b in human superficial bladder cancer vs invasive bladder cancer. Br J Cancer. 1998, 77 (2): 319-324. 10.1038/bjc.1998.49.PubMed CentralView ArticlePubMedGoogle Scholar
- Mikels AJ, Nusse R: Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol. 2006, 4 (4): e115-10.1371/journal.pbio.0040115.PubMed CentralView ArticlePubMedGoogle Scholar
- Gordon MD, Nusse R: Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem. 2006, 281 (32): 22429-22433. 10.1074/jbc.R600015200.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.